Clinical and Pharmacological Effects of Substance BZ-55 in Diabetes: (p-Aminophenylsulfonyl Butylcarbamide)

Kirtley, W R; Ridolfo, A S; Root, M A; Anderson, R C

doi:10.2337/diab.5.5.351

W R Kirtley, M.D.;

W R Kirtley, M.D.

Senior Physician

Lilly Laboratory for Clinical Research and Lilly Research Laboratories

Indianapolis, Indiana

Search for other works by this author on:

This Site

PubMed

Google Scholar

A S Ridolfo, M.D., Ph.D.;

A S Ridolfo, M.D., Ph.D.

Lilly Laboratory for Clinical Research and Lilly Research Laboratories

Indianapolis, Indiana

Search for other works by this author on:

This Site

PubMed

Google Scholar

M A Root, Ph.D.;

M A Root, Ph.D.

Pharmacologist

Lilly Laboratory for Clinical Research and Lilly Research Laboratories

Indianapolis, Indiana

Search for other works by this author on:

This Site

PubMed

Google Scholar

R C Anderson, D.Sc.

Head

Lilly Laboratory for Clinical Research and Lilly Research Laboratories

Indianapolis, Indiana

Search for other works by this author on:

This Site

PubMed

Google Scholar

Lilly Laboratory for Clinical Research. Associate in Medicine, Indiana University Medical School.

†

Resident in Medicine, Indianapolis General Hospital.

‡

Lilly Research Laboratories.

Department of Toxicology, Lilly Research Laboratories.

Clinical and Pharmacological Effects of Substance BZ-55 in Diabetes: (p-Aminophenylsulfonyl Butylcarbamide)

Article PDF first page preview

Email alerts

Journals

Books

News

Other

About

Resources

Clinical and Pharmacological Effects of Substance BZ-55 in Diabetes: (p-Aminophenylsulfonyl Butylcarbamide)

Article PDF first page preview

Email alerts

Journals

Books

News

Other

About

Resources

This Feature Is Available To Subscribers Only